Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M
Source: SeekingAlpha
2026-03-05 17:56:44 ET
More on Evommune, Inc.
- Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge
- Evommune raises $125M privately
- Evommune surges on mid-stage trial win for eczema therapy
- Seeking Alpha’s Quant Rating on Evommune, Inc.
- Historical earnings data for Evommune, Inc.
Read the full article on Seeking Alpha
For further details see:
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M
Evommune Inc.
NASDAQ: EVMN
EVMN Trading
2.25% G/L:
$25.47 Last:
150,490 Volume:
$25.34 Open:
EVMN Latest News
March 10, 2026 10:11:00 am
1 Under?the?Radar Biotech to Buy for Potential 10X Growth in the Next Decade
March 05, 2026 04:01:00 pm
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
EVMN Stock Data
$915,144,420
15,720,750
0.25%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
